Emerging functions and therapeutic targets of IL‐38 in central nervous system diseases
Yuan Gao,Luwei Cai,Yulu Wu,Min Jiang,Yidan Zhang,Wenjing Ren,Yirui Song,Lili Li,Ziguang Lei,Youzhuang Wu,Luwen Zhu,Jing Li,Dongya Li,Guohong Li,Chengliang Luo,Luyang Tao
DOI: https://doi.org/10.1111/cns.14550
2024-02-11
CNS Neuroscience & Therapeutics
Abstract:IL‐38 regulates immune and inflammatory responses after NMOD, AD, ASD, IS, TBI, and SCI by competitively binding to IL36R with IL‐36. Briefly, IL‐38 recruits myeloid differentiation primary response 88 (MyD88) by binding to IL‐1R1 or IL‐36R, activating downstream signaling pathways including NF‐κB and MAPK pathways, thereby enhancing the production of pro‐inflammatory cytokines and chemokines. In addition, IL‐38 selectively recruits MEK or upregulates channel protein‐dependent SIRT1 by binding to IL1RAPL1, thereby reducing NF‐κB, AP‐1, and MAPK. Interleukin (IL)‐38 is a newly discovered cytokine of the IL‐1 family, which binds various receptors (i.e., IL‐36R, IL‐1 receptor accessory protein‐like 1, and IL‐1R1) in the central nervous system (CNS). The hallmark physiological function of IL‐38 is competitive binding to IL‐36R, as does the IL‐36R antagonist. Emerging research has shown that IL‐38 is abnormally expressed in the serum and brain tissue of patients with ischemic stroke (IS) and autism spectrum disorder (ASD), suggesting that IL‐38 may play an important role in neurological diseases. Important advances include that IL‐38 alleviates neuromyelitis optica disorder (NMOD) by inhibiting Th17 expression, improves IS by protecting against atherosclerosis via regulating immune cells and inflammation, and reduces IL‐1β and CXCL8 release through inhibiting human microglial activity post‐ASD. In contrast, IL‐38 mRNA is markedly increased and is mainly expressed in phagocytes in spinal cord injury (SCI). IL‐38 ablation attenuated SCI by reducing immune cell infiltration. However, the effect and underlying mechanism of IL‐38 in CNS diseases remain inadequately characterized. In this review, we summarize the biological characteristics, pathophysiological role, and potential mechanisms of IL‐38 in CNS diseases (e.g., NMOD, Alzheimer's disease, ASD, IS, TBI, and SCI), aiming to explore the therapeutic potential of IL‐38 in the prevention and treatment of CNS diseases.
pharmacology & pharmacy,neurosciences